MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$1,069K
Net Income
$1,482K
Net Profit Margin
138.63%
EPS
-$0.03
Unit: Thousand (K) dollars
Revenue Breakdown
Upfront License Fees
Event Based Milestones And Other...
Royalties, license and other rev...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
1,069
-
6,608
3,681
Cost of royalties
0
-
80*
5
Research and development
4,774
-
8,238
3,271
General and administrative
5,218
-
4,852
4,191
Gain on impairment of intangible asset (note 6 and note 13)
0
-
-14*
0
Total operating expenses
9,992
-
13,156
7,467
Loss from operations
-8,923
-
-6,548
-3,786
Interest income, net
378
-
393
366
Gain (loss) on marketable equity securities, net
0
-
-7
6
Change in fair value of warrant liability
-9,443
-
-1,265
26,557
Foreign currency transaction gain, net
664
-
482
219
Other income (expense), net
-18
-
27
0
Total other income (expenses)
10,467
-
2,160
-25,966
Net loss
1,544
-
-428*
-
Income tax benefit
-
-
-1,320*
-
Net income (gain)
1,544
-4,789
892
-29,752
Net (income) loss attributable to noncontrolling interest
62
23
41
29
Net income (gain) attributable to lineage
1,482
-4,812
851
-29,781
Basic EPS
0.01
-0.02
0.004
-0.13
Diluted EPS
-0.03
-0.03
0.004
-0.13
Basic Average Shares
249,499,000
245,029,000
237,201,000
228,853,000
Diluted Average Shares
261,471,000
261,175,000
237,201,000
228,853,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Change in fair value of
warrant liability
-$9,443K
(-174.12%↓ Y/Y)
Foreign currency
transaction gain, net
$664K
(-60.43%↓ Y/Y)
Interest income, net
$378K
(-16.74%↓ Y/Y)
Upfront License Fees
$600K
(-76.30%↓ Y/Y)
Event Based
Milestones And Other...
$343K
Total other income
(expenses)
$10,467K
(198.89%↑ Y/Y)
Other income
(expense), net
-$18K
(-169.23%↓ Y/Y)
Total revenues under
collaborative agreements
$943K
(-62.76%↓ Y/Y)
Royalties, license and
other revenues
$126K
(-45.92%↓ Y/Y)
Net loss
$1,544K
(105.08%↑ Y/Y)
Loss from operations
-$8,923K
(54.89%↑ Y/Y)
Total revenues
$1,069K
(-61.34%↓ Y/Y)
Net income (gain)
$1,544K
(105.08%↑ Y/Y)
Total operating
expenses
$9,992K
(-55.68%↓ Y/Y)
Net income (gain)
attributable to lineage
$1,482K
(104.86%↑ Y/Y)
Net (income) loss
attributable to...
$62K
(-38.00%↓ Y/Y)
General and
administrative
$5,218K
(14.43%↑ Y/Y)
Research and development
$4,774K
(53.70%↑ Y/Y)
Buy us a coffee
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)